Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 200
Filter
1.
Mol Microbiol ; 118(1-2): 3-15, 2022 07.
Article in English | MEDLINE | ID: mdl-35611562

ABSTRACT

A significant portion of clinically observed antifungal resistance is mediated by ATP-binding cassette (ABC) and major facilitator superfamily (MFS) transport pumps that reside in the plasma membrane. We review the mechanisms responsible for this phenomenon. Hyper resistance is often brought about by several kinds of DNA amplification or by gain-of-function mutations in a variety of transcription factors. Both of these result in overexpression of ABC and MFS transporters. Recently, however, several additional modes of resistance have been observed. These include mutations in non-conserved nucleotides leading to altered mRNA stability and a mutation in yeast transporter Pdr5, which improves cooperativity between drug-binding sites.


Subject(s)
ATP-Binding Cassette Transporters , Drug Resistance, Fungal , Membrane Transport Proteins , Saccharomyces cerevisiae Proteins , Saccharomyces cerevisiae , ATP-Binding Cassette Transporters/genetics , ATP-Binding Cassette Transporters/metabolism , Antifungal Agents/adverse effects , Antifungal Agents/metabolism , DNA/genetics , DNA/metabolism , Drug Resistance, Fungal/genetics , Drug Resistance, Fungal/physiology , Membrane Transport Proteins/genetics , Membrane Transport Proteins/metabolism , Mutation , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Saccharomyces cerevisiae/pathogenicity , Saccharomyces cerevisiae Proteins/genetics , Saccharomyces cerevisiae Proteins/metabolism
2.
PLoS Pathog ; 17(12): e1010073, 2021 12.
Article in English | MEDLINE | ID: mdl-34882756

ABSTRACT

Fungal infections are underestimated threats that affect over 1 billion people, and Candida spp., Cryptococcus spp., and Aspergillus spp. are the 3 most fatal fungi. The treatment of these infections is performed with a limited arsenal of antifungal drugs, and the class of the azoles is the most used. Although these drugs present low toxicity for the host, there is an emergence of therapeutic failure due to azole resistance. Drug resistance normally develops in patients undergoing azole long-term therapy, when the fungus in contact with the drug can adapt and survive. Conversely, several reports have been showing that resistant isolates are also recovered from patients with no prior history of azole therapy, suggesting that other routes might be driving antifungal resistance. Intriguingly, antifungal resistance also happens in the environment since resistant strains have been isolated from plant materials, soil, decomposing matter, and compost, where important human fungal pathogens live. As the resistant fungi can be isolated from the environment, in places where agrochemicals are extensively used in agriculture and wood industry, the hypothesis that fungicides could be driving and selecting resistance mechanism in nature, before the contact of the fungus with the host, has gained more attention. The effects of fungicide exposure on fungal resistance have been extensively studied in Aspergillus fumigatus and less investigated in other human fungal pathogens. Here, we discuss not only classic and recent studies showing that environmental azole exposure selects cross-resistance to medical azoles in A. fumigatus, but also how this phenomenon affects Candida and Cryptococcus, other 2 important human fungal pathogens found in the environment. We also examine data showing that fungicide exposure can select relevant changes in the morphophysiology and virulence of those pathogens, suggesting that its effect goes beyond the cross-resistance.


Subject(s)
Antifungal Agents/therapeutic use , Drug Resistance, Fungal/drug effects , Drug Resistance, Fungal/physiology , Fungicides, Industrial/pharmacology , Mycoses/drug therapy , Azoles/pharmacology , Humans
3.
Nat Commun ; 12(1): 6235, 2021 10 29.
Article in English | MEDLINE | ID: mdl-34716343

ABSTRACT

The fungal pathogen Candida albicans can form biofilms that protect it from drugs and the immune system. The biofilm cells release extracellular vesicles (EVs) that promote extracellular matrix formation and resistance to antifungal drugs. Here, we define functions for numerous EV cargo proteins in biofilm matrix assembly and drug resistance, as well as in fungal cell adhesion and dissemination. We use a machine-learning analysis of cargo proteomic data from mutants with EV production defects to identify 63 candidate gene products for which we construct mutant and complemented strains for study. Among these, 17 mutants display reduced biofilm matrix accumulation and antifungal drug resistance. An additional subset of 8 cargo mutants exhibit defects in adhesion and/or dispersion. Representative cargo proteins are shown to function as EV cargo through the ability of exogenous wild-type EVs to complement mutant phenotypic defects. Most functionally assigned cargo proteins have roles in two or more of the biofilm phases. Our results support that EVs provide community coordination throughout biofilm development in C. albicans.


Subject(s)
Biofilms/growth & development , Candida albicans/physiology , Drug Resistance, Fungal/physiology , Extracellular Vesicles/metabolism , Fungal Proteins/metabolism , Animals , Antifungal Agents/pharmacology , Biofilms/drug effects , Candida albicans/cytology , Candida albicans/drug effects , Candida albicans/pathogenicity , Candidiasis/microbiology , Cell Adhesion/drug effects , Central Venous Catheters/microbiology , Drug Resistance, Fungal/drug effects , Endosomal Sorting Complexes Required for Transport/metabolism , Extracellular Matrix/chemistry , Extracellular Vesicles/chemistry , Female , Fungal Proteins/genetics , Mutation , Rats
4.
Microb Drug Resist ; 27(10): 1371-1388, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33956513

ABSTRACT

Candida glabrata is the second frequent etiologic agent of mucosal and invasive candidiasis. Based on the recent developments in molecular methods, C. glabrata has been introduced as a complex composed of C. glabrata, Candida nivariensis, and Candida bracarensis. The four main classes of antifungal drugs effective against C. glabrata are pyrimidine analogs (flucytosine), azoles, echinocandins, and polyenes. Although the use of antifungal drugs is related to the predictable development of drug resistance, it is not clear why C. glabrata is able to rapidly resist against multiple antifungals in clinics. The enhanced incidence and antifungal resistance of C. glabrata and the high mortality and morbidity need more investigation regarding the resistance mechanisms and virulence associated with C. glabrata; additional progress concerning the drug resistance of C. glabrata has to be further prevented. The present review highlights the mechanism of resistance to antifungal drugs in C. glabrata.


Subject(s)
Antifungal Agents/pharmacology , Candida glabrata/drug effects , Candida glabrata/physiology , Drug Resistance, Fungal/physiology , Azoles/pharmacology , Drug Resistance, Fungal/genetics , Echinocandins/pharmacology , Global Health , Polyenes/pharmacology , Pyrimidines/pharmacology
5.
Lett Appl Microbiol ; 72(6): 688-697, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33550599

ABSTRACT

Candida albicans is one of the most common clinical pathogenic microorganisms and it is becoming a serious health threat, particularly to immunocompromised populations. Drug resistance of Candida species has also frequently emerged, and combination therapy for fungal infections has attracted considerable attention. In this study, we established the Qinling Mountains myxobacterial secondary metabolites library and a synergic assay in combination with ketoconazole against C. albicans was introduced for metabolites screening. Two active compounds with synergic anticandidal activities were obtained, which were identified as trans-resveratrol and cis-resveratrol. According to our study, resveratrol can reduce the dosage to 1/64 of ketoconazole as well as itraconazole. Furthermore, synergistic anticandidal activity of resveratrol combined with azoles was verified against a panel of clinical C. albicans isolates, and the combination strategy enhanced the azoles susceptibility of three fluconazole-resistant isolates. These findings suggest that resveratrol enhances the efficacy of azoles and provides a promising application in therapy of C. albicans infection.


Subject(s)
Antifungal Agents/pharmacology , Azoles/pharmacology , Candida albicans/drug effects , Mycoses/drug therapy , Resveratrol/pharmacology , Drug Resistance, Fungal/physiology , Drug Synergism , Drug Therapy, Combination , Fluconazole/pharmacology , Humans , Itraconazole/pharmacology , Microbial Sensitivity Tests
6.
mBio ; 12(1)2021 01 12.
Article in English | MEDLINE | ID: mdl-33436441

ABSTRACT

The human fungal pathogen Cryptococcus neoformans is intrinsically resistant to the echinocandin antifungal drug caspofungin, which targets the ß-1,3-glucan synthase encoded by FKS1 Echinocandins have been on the market for 20 years, yet they are the newest class of antifungal drugs. Analysis of a C. neoformanspuf4Δ mutant, lacking the pumilio/FBF RNA binding protein family member Puf4, revealed exacerbated caspofungin resistance. In contrast, overexpression of PUF4 resulted in caspofungin sensitivity. The FKS1 mRNA contains three Puf4-binding elements (PBEs) in its 5' untranslated region. Puf4 binds with specificity to this region of FKS1 The FKS1 mRNA was destabilized in the puf4Δ mutant, and the abundance of the FKS1 mRNA was reduced compared to wild type, suggesting that Puf4 is a positive regulator of FKS1 mRNA stability. In addition to FKS1, the abundance of additional cell wall biosynthesis genes, including chitin synthases (CHS3, CHS4, and CHS6) and deacetylases (CDA1, CDA2, and CDA3) as well as a ß-1,6-glucan synthase gene (SKN1), was regulated by Puf4. The use of fluorescent dyes to quantify cell wall components revealed that the puf4Δ mutant had increased chitin content, suggesting a cell wall composition that is less reliant on ß-1,3-glucan. Overall, our findings suggest a mechanism by which caspofungin resistance, and more broadly, cell wall biogenesis, is regulated post-transcriptionally by Puf4.IMPORTANCECryptococcus neoformans is an environmental fungus that causes pulmonary and central nervous system infections. It is also responsible for 15% of AIDS-related deaths. A significant contributor to the high morbidity and mortality statistics is the lack of safe and effective antifungal therapies, especially in resource-poor settings. Yet, antifungal drug development has stalled in the pharmaceutical industry. Therefore, it is essential to understand the mechanism by which C. neoformans is resistant to caspofungin to design adjunctive therapies to potentiate the drug's activity toward this important pathogen.


Subject(s)
Caspofungin/pharmacology , Cell Wall/drug effects , Cell Wall/genetics , Cryptococcus neoformans/drug effects , Cryptococcus neoformans/genetics , Drug Resistance, Fungal/genetics , Antifungal Agents/pharmacology , Cell Wall/metabolism , Chitin/metabolism , Chitin Synthase/metabolism , Cryptococcosis/microbiology , Drug Resistance, Fungal/physiology , Echinocandins , Fungal Proteins/genetics , Fungal Proteins/metabolism , Glucans/metabolism , Glucosyltransferases/genetics , Glucosyltransferases/metabolism , Humans , Membrane Proteins/genetics , Membrane Proteins/metabolism , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Saccharomyces cerevisiae Proteins , beta-Glucans/metabolism
7.
Genes (Basel) ; 11(11)2020 10 30.
Article in English | MEDLINE | ID: mdl-33143139

ABSTRACT

Iron is a key transition metal required by most microorganisms and is prominently utilised in the transfer of electrons during metabolic reactions. The acquisition of iron is essential and becomes a crucial pathogenic event for opportunistic fungi. Iron is not readily available in the natural environment as it exists in its insoluble ferric form, i.e., in oxides and hydroxides. During infection, the host iron is bound to proteins such as transferrin, ferritin, and haemoglobin. As such, access to iron is one of the major hurdles that fungal pathogens must overcome in an immunocompromised host. Thus, these opportunistic fungi utilise three major iron acquisition systems to overcome this limiting factor for growth and proliferation. To date, numerous iron acquisition pathways have been fully characterised, with key components of these systems having major roles in virulence. Most recently, proteins involved in these pathways have been linked to the development of antifungal resistance. Here, we provide a detailed review of our current knowledge of iron acquisition in opportunistic fungi, and the role iron may have on the development of resistance to antifungals with emphasis on species of the fungal basal lineage order Mucorales, the causative agents of mucormycosis.


Subject(s)
Iron/metabolism , Mucormycosis/metabolism , Mycoses/metabolism , Animals , Antifungal Agents/pharmacology , Drug Resistance, Fungal/genetics , Drug Resistance, Fungal/physiology , Humans , Mucorales/genetics , Mucorales/metabolism , Mucormycosis/drug therapy , Mycoses/physiopathology , Opportunistic Infections/metabolism , Virulence
8.
Can J Microbiol ; 66(12): 733-747, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32777192

ABSTRACT

Candidiasis caused by multidrug-resistant Candida species continues to be difficult to eradicate. The use of live probiotic bacteria has gained a lot of interest in the treatment of candidiasis; however, whole-cell probiotic use can often be associated with a high risk of sepsis. Strategies manipulating cell-free methods using probiotic strains could lead to the development of novel antifungal solutions. Therefore, we evaluated the effect of three probiotic cell-free extracts (CFEs) on the growth, virulence traits, and drug efflux pumps in C. albicans. On the basis of its minimum inhibitory concentration, Lactobacillus rhamnosus was selected and assessed against various virulence traits and drug resistance mechanisms. The results showed that L. rhamnosus CFE significantly inhibited hyphae formation and reduced secretion of proteinases and phospholipases. Moreover, L. rhamnosus inhibited the drug efflux proteins in resistant C. albicans strains thus reversing drug resistance. Gene expression data confirmed downregulation of genes associated with microbial virulence and drug resistance following treatment of C. albicans with L. rhamnosus CFE. Through gas chromatography - mass spectrometry chemical characterization, high contents of oleic acid (24.82%) and myristic acid (13.11%) were observed in this CFE. Collectively, our findings indicate that L. rhamnosus may potentially be used for therapeutic purposes to inhibit C. albicans infections.


Subject(s)
Antibiosis/physiology , Candida albicans/drug effects , Candidiasis/microbiology , Drug Resistance, Fungal/physiology , Lacticaseibacillus rhamnosus/physiology , Probiotics , Antifungal Agents/pharmacology , Biofilms , Candida albicans/pathogenicity , Humans , Lacticaseibacillus rhamnosus/chemistry , Virulence/drug effects
9.
Mol Microbiol ; 114(5): 721-734, 2020 11.
Article in English | MEDLINE | ID: mdl-32697029

ABSTRACT

Fungal infections are a global concern and the evolution of intrinsic resistance to current antifungals presents an alarming problem. For Cryptococcus neoformans, a human fungal pathogen of primarily immunocompromised individuals, resistance toward treatment strategies demands alternative approaches. Given the prevalence of virulence factor production during cryptococcal infection, an emerging and important field of research encompasses the development of novel antivirulence therapies proposed to improve host immune responses and promote fungal clearance. To accomplish this task, information regarding the presence and role of virulence factors, the mechanisms of action within the host, and the ability to influence fungal susceptibility to antifungals is pertinent. Research into mechanisms of antifungal resistance for C. neoformans is limited but extrapolation from successful studies in other fungal species can improve our understanding of mechanisms employed by C. neoformans and suggest targeted strategies to enhance our ability to combat the pathogen. In this Review, we highlight antifungal therapy options against Cryptococcus, explore current knowledge of underlying mechanisms promoting resistance, and present new opportunities for novel and effective strategies to overcome fungal infections and reduce, or possibly even reverse, the effects of resistance evolution.


Subject(s)
Cryptococcosis/therapy , Cryptococcus neoformans/metabolism , Drug Resistance, Fungal/genetics , Antifungal Agents/pharmacology , Cryptococcosis/microbiology , Cryptococcus neoformans/genetics , Cryptococcus neoformans/pathogenicity , Drug Resistance, Fungal/physiology , Humans , Virulence/drug effects , Virulence Factors
10.
Int J Food Microbiol ; 333: 108795, 2020 Nov 16.
Article in English | MEDLINE | ID: mdl-32721627

ABSTRACT

In recent times green tea (GT) consumption has increased, due to the numerous studies that indicate a wide variety of health benefits following its regular consumption. The aim of this study was to assess the bioburden (bacteria and fungi) of bulk and bags of GT marketed in Lisbon and to obtain a more refined fungal burden characterization, including azole resistance profile. The bacteriota in tea bags before boiling ranged from lower than the detection limit to 1770 CFU.g-1, whereas in brew samples ranged from lower than the detection limit to 54.55 CFU.mL-1. In bulk samples before boiling ranged from lower than the detection limit to 2636 CFU.g-1, while after boiling ranged from lower than the detection limit to 72.73 CFU.mL-1. Fungal contamination on tea bags before boiling ranged from lower than the detection limit to 66.67 CFU.g-1 and after boiling, all samples presented results lower than the detection limit. Concerning bulk samples before boiling ranged from lower than the detection limit to 96.97 CFU.g-1, whereas after boiling ranged from lower the detection limit to 30.3 CFU.mL-1. Before boiling, the most common fungal species in the bagged tea (90.91 CFU.g-1; 45.45%) and bulk samples (66.67 CFU.g-1; 91.67%) was Aspergillus section Nigri. Fungal diversity was higher on bulk samples than in tea bags. Aspergillus section Nigri and Rhizopus sp. growth was observed mostly on itraconazole-supplemented Sabouraud dextrose agar media, which require further investigation. Aspergillus sections Fumigati and Nidulantes were detected by using real time PCR, but not in the GT samples in which they were identified through culture-based methods. A significantly reduction of bacterial contamination after boiling was observed, however fungal contamination with toxigenic potential was observed before and after boiling. Future research work needs to characterize in detail the mycotoxins contamination to allow a risk-benefit assessment to estimate the human health benefits and risks following tea consumption and to support policy-actions, if and when needed. The results also suggest that the conditions how tea is packed can influence the fungal diversity and this variable should be further investigated.


Subject(s)
Anti-Infective Agents/pharmacology , Aspergillus/isolation & purification , Azoles/pharmacology , Bacteria/isolation & purification , Drug Resistance, Bacterial/physiology , Drug Resistance, Fungal/physiology , Tea/microbiology , Aspergillus/drug effects , Aspergillus/genetics , Bacteria/drug effects , Bacteria/genetics , Food Contamination/analysis , Humans , Microbial Sensitivity Tests , Mycotoxins/analysis , Portugal , Real-Time Polymerase Chain Reaction
11.
J Med Chem ; 63(10): 5341-5359, 2020 05 28.
Article in English | MEDLINE | ID: mdl-32347094

ABSTRACT

Invasive fungal infections (particularly candidiasis) are emerging as severe infectious diseases worldwide. Because of serious antifungal drug resistance, therapeutic efficacy of the current treatment for candidiasis is limited and associated with high mortality. However, it is highly challenging to develop novel strategies and effective therapeutic agents to combat drug resistance. Herein, the first generation of lanosterol 14α-demethylase (CYP51)-histone deacetylase (HDAC) dual inhibitors was designed, which exhibited potent antifungal activity against azole-resistant clinical isolates. In particular, compounds 12h and 15j were highly active both in vitro and in vivo to treat azole-resistant candidiasis. Antifungal mechanism studies revealed that they acted by blocking ergosterol biosynthesis and HDAC catalytic activity in fungus, suppressing the function of efflux pump, yeast-to-hypha morphological transition, and biofilm formation. Therefore, CYP51-HDAC dual inhibitors represent a promising strategy to develop novel antifungal agents against azole-resistant candidiasis.


Subject(s)
14-alpha Demethylase Inhibitors/metabolism , Azoles/pharmacology , Candidiasis/metabolism , Drug Discovery/methods , Drug Resistance, Fungal/drug effects , Histone Deacetylase Inhibitors/metabolism , Sterol 14-Demethylase/metabolism , 14-alpha Demethylase Inhibitors/administration & dosage , 14-alpha Demethylase Inhibitors/chemistry , Animals , Azoles/therapeutic use , Candida albicans/drug effects , Candida albicans/physiology , Candidiasis/drug therapy , Cytochrome P450 Family 51/antagonists & inhibitors , Cytochrome P450 Family 51/chemistry , Cytochrome P450 Family 51/metabolism , Drug Resistance, Fungal/physiology , Female , Histone Deacetylase Inhibitors/administration & dosage , Histone Deacetylase Inhibitors/chemistry , Human Umbilical Vein Endothelial Cells , Humans , Mice , Mice, Inbred ICR , Sterol 14-Demethylase/chemistry , Treatment Outcome
12.
Eur J Hosp Pharm ; 27(1): 14-18, 2020 01.
Article in English | MEDLINE | ID: mdl-32064083

ABSTRACT

Background: Although antimicrobial stewardship programmes are one of the highest priorities in healthcare systems and many articles have been published, few refer to the implementation of antifungal stewardship and highlight specific points on which efforts should be focused. Objective: To assess the percentage of patients with confirmed candidaemia in whom de-escalation was conducted, and the economic impact of step-down or step-up antifungal therapy. Additionally, we attempted to estimate the potential increase in drug minimum inhibitory concentrations or to detect resistant strains of Candida species. Methods: We selected, retrospectively, patients who had received systemic antifungal therapy between 2011 and 2016 for documented candidaemia. Statistical analysis and diagrams were used to assess the results. Results: Of 157 patients with confirmed candidaemia, 58 received azoles, 74 echinocandinsand 18 liposomal amphotericin B for empirical therapy. 51 patients were eligible to step-down to fluconazole but only 23 patients did so. Furthermore, in nine patients unjustified step-up from fluconazole to echinocandins or liposomal amphotericin B was carried out. The additional cost incurred bythe healthcare system due to high prices of echinocandins and liposomal amphotericin B in comparison with fluconazole was€211 837. Interestingly, it was found that one strain of C. albicans and two strains of C. glabrata were resistant to echinocandins. Conclusion: The presence of a multidisciplinary team, including an infection control specialist and a clinical pharmacist, would limit the prescription of advanced antifungal agents as empirical therapy. Moreover, this team would control the de-escalation process-where applicable-leading to a reduction in costs and, probably, a decrease in the emergence of resistant Candida species. These facts contribute to the broader discussion on the adoption of antifungal stewardship programmes.


Subject(s)
Antifungal Agents/administration & dosage , Candidemia/drug therapy , Drug Resistance, Fungal/drug effects , Drug Utilization Review/standards , Amphotericin B/administration & dosage , Amphotericin B/adverse effects , Antifungal Agents/adverse effects , Candidemia/epidemiology , Drug Resistance, Fungal/physiology , Drug Utilization Review/methods , Echinocandins/administration & dosage , Echinocandins/adverse effects , Humans , Microbial Sensitivity Tests/methods , Microbial Sensitivity Tests/standards , Retrospective Studies
13.
Article in English | MEDLINE | ID: mdl-32015043

ABSTRACT

We evaluated the activity of rezafungin and comparators, using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods, against a worldwide collection of 2,205 invasive fungal isolates recovered from 2016 to 2018. Candida (n = 1,904 isolates; 6 species), Cryptococcus neoformans (n = 73), Aspergillus fumigatus (n = 183), and Aspergillus flavus (n = 45) isolates were tested for their susceptibility (S) to rezafungin as well as the comparators caspofungin, anidulafungin, micafungin, and azoles. Interpretive criteria were applied following CLSI published clinical breakpoints (CBPs) and epidemiological cutoff values (ECVs). Isolates displaying non-wild-type (non-WT) echinocandin MIC values were sequenced for hot spot (HS) mutations. Rezafungin inhibited 99.8% of Candida albicans isolates (MIC50/90, 0.03/0.06 µg/ml), 95.7% of Candida glabrata isolates (MIC50/90, 0.06/0.12 µg/ml), 97.4% of Candida tropicalis isolates (MIC50/90, 0.03/0.06 µg/ml), 100.0% of Candida krusei isolates (MIC50/90, 0.03/0.06 µg/ml), and 100.0% of Candida dubliniensis isolates (MIC50/90, 0.06/0.12 µg/ml) at ≤0.12 µg/ml. All (329/329 [100.0%]) Candida parapsilosis isolates (MIC50/90,1/2 µg/ml) were inhibited by rezafungin at ≤4 µg/ml. Fluconazole resistance was detected among 8.6% of C. glabrata isolates, 12.5% of C. parapsilosis isolates, 3.2% of C. dubliniensis isolates, and 2.6% of C. tropicalis isolates. The activity of rezafungin against these 6 Candida spp. was similar to the activity of the other echinocandins. Detection of the HS mutation was performed by sequencing echinocandin-resistant or non-WT Candida isolates. Good activity against C. neoformans was observed for fluconazole and the other azoles, whereas the echinocandins, including rezafungin, displayed limited activity. Rezafungin displayed activity similar to that of the other echinocandins against A. fumigatus and A. flavus These in vitro data contribute to accumulating research demonstrating the potential of rezafungin for preventing and treating invasive fungal infections.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus flavus/drug effects , Aspergillus fumigatus/drug effects , Candida/drug effects , Cryptococcus neoformans/drug effects , Echinocandins/pharmacology , Anidulafungin/pharmacology , Aspergillus flavus/isolation & purification , Aspergillus fumigatus/isolation & purification , Azoles/pharmacology , Candida/isolation & purification , Caspofungin/pharmacology , Cryptococcus neoformans/isolation & purification , Drug Resistance, Fungal/physiology , Humans , Micafungin/pharmacology , Microbial Sensitivity Tests
14.
Clin Respir J ; 14(6): 571-577, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32077238

ABSTRACT

INTRODUCTION: Chronic pulmonary aspergillosis (CPA) is a fungal disease with high mortality and morbidity. Guidelines suggest treatment with azoles as first-line therapy. However, patients often develop treatment intolerance or increasingly azole resistance. OBJECTIVES: This retrospective review assesses outcomes in azole resistant or intolerant patients with CPA treated with cyclical echinocandin therapy. METHODS: We retrospectively examined records of 25 patients with CPA treated with cyclical caspofungin, 6 of whom were either azole-resistant or azole intolerant. Baseline characteristics, high-resolution computed tomography severity scores, forced expiratory volume after 1 minute (FEV1), forced vital capacity (FVC), body mass index and serology (Aspergillus fumigatus-specific IgG, Aspergillus fumigatus-specific IgE, total IgE and CRP) were assessed before and after caspofungin. RESULTS: Of the six patients, four (66%) started caspofungin due to intolerance and two (33%) due to pan-azole resistance. On treatment, there was stability in FEV1 with an overall mortality of 33% during the follow-up period with a median survival of 875.5 days (IQR 529-1024). No significant change in serology (A. fumigatus-specific IgG and CRP was seen. CONCLUSIONS: With pulsed echinocandin therapy, azole-intolerant or pan-resistant CPA patients have similar mortality rates to azole-naïve CPA patients. Pulsed echinocandin therapy may present a strategy to stabilize CPA in patients with pan resistance or intolerance to, azole therapy.


Subject(s)
Antifungal Agents/therapeutic use , Azoles/standards , Echinocandins/therapeutic use , Pulmonary Aspergillosis/drug therapy , Administration, Intravenous , Adult , Aged , Antifungal Agents/administration & dosage , Aspergillus fumigatus/immunology , Azoles/therapeutic use , Biomarkers/blood , Caspofungin/administration & dosage , Caspofungin/therapeutic use , Chronic Disease , Drug Resistance, Fungal/physiology , Echinocandins/administration & dosage , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/therapeutic use , Female , Humans , Male , Middle Aged , Outcome Assessment, Health Care , Pulmonary Aspergillosis/diagnostic imaging , Pulmonary Aspergillosis/mortality , Pulmonary Aspergillosis/physiopathology , Respiratory Function Tests/methods , Retrospective Studies , Tomography, X-Ray Computed/methods , United Kingdom/epidemiology
15.
Proc Natl Acad Sci U S A ; 117(3): 1711-1721, 2020 01 21.
Article in English | MEDLINE | ID: mdl-31811023

ABSTRACT

Drug resistance in fungal pathogens has risen steadily over the past decades due to long-term azole therapy or triazole usage in agriculture. Modification of the drug target protein to prevent drug binding is a major recognized route to induce drug resistance. However, mechanisms for nondrug target-induced resistance remain only loosely defined. Here, we explore the molecular mechanisms of multidrug resistance resulted from an efficient adaptation strategy for survival in drug environments in the human pathogen Aspergillus fumigatus We show that mutants conferring multidrug resistance are linked with mitochondrial dysfunction induced by defects in heme A biosynthesis. Comparison of the gene expression profiles between the drug-resistant mutants and the parental wild-type strain shows that multidrug-resistant transporters, chitin synthases, and calcium-signaling-related genes are significantly up-regulated, while scavenging mitochondrial reactive oxygen species (ROS)-related genes are significantly down-regulated. The up-regulated-expression genes share consensus calcium-dependent serine threonine phosphatase-dependent response elements (the binding sites of calcium-signaling transcription factor CrzA). Accordingly, drug-resistant mutants show enhanced cytosolic Ca2+ transients and persistent nuclear localization of CrzA. In comparison, calcium chelators significantly restore drug susceptibility and increase azole efficacy either in laboratory-derived or in clinic-isolated A. fumigatus strains. Thus, the mitochondrial dysfunction as a fitness cost can trigger calcium signaling and, therefore, globally up-regulate a series of embedding calcineurin-dependent-response-element genes, leading to antifungal resistance. These findings illuminate how fitness cost affects drug resistance and suggest that disruption of calcium signaling might be a promising therapeutic strategy to fight against nondrug target-induced drug resistance.


Subject(s)
Aspergillus fumigatus/drug effects , Calcium Signaling/physiology , Drug Resistance, Fungal/drug effects , Drug Resistance, Fungal/physiology , Mitochondria/drug effects , Mitochondria/metabolism , Mitochondrial Diseases/metabolism , Alkyl and Aryl Transferases/genetics , Antifungal Agents/pharmacology , Aspergillus fumigatus/genetics , Calcium Chelating Agents/pharmacology , Calcium Signaling/drug effects , Chitin Synthase/genetics , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Gene Expression Regulation, Fungal/drug effects , Heme/analogs & derivatives , Heme/biosynthesis , Humans , Membrane Proteins/genetics , Mitochondria/genetics , Mitochondrial Diseases/genetics , Phosphoprotein Phosphatases/metabolism , Reactive Oxygen Species , Transcription Factors/metabolism , Triazoles/pharmacology
16.
Medicine (Baltimore) ; 98(41): e17535, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31593129

ABSTRACT

Scedosporium genus as a significant emerging opportunist causes a broad spectrum of disease in not only immunosuppressed but also immunocompetent patients. The lung is one of the most commonly encountered sites of Scedosporium infection. Due to its very high levels of antifungal resistance, surgery has been recommended as an important part in the treatment of pulmonary Scedosporium spp infection, even in immunocompetent cases. However, whether lung surgery could help to reduce the risk of death in immunocompetent patients is not clear.We retrospectively retrieved the records of pulmonary infections with Scedosporium species in immunocompetent patients through a comprehensive literature search. The association of surgery on all-cause mortality was explored using binary logistic regression (BLR). Receiver operating characteristic (ROC) curve analysis was carried out to evaluate the capability of the model.The comprehensive searching strategy yielded 33 case reports and 3 case series in total, with 40 individual patients being included. The overall mortality was 12.50%. The fatality rate was 9.09% (2/22) in cases with surgery and 16.67% (3/18) in cases without surgery (odds ratio, 0.50; 95% confidence interval, 0.07-3.38; P = .48). Consistently, BLR analysis identified no statistical association between surgery and reduced mortality (odds ratio, 1.19; 95% confidence interval, 0.09-15.64; P = .89), after adjusting for age, gender, and antifungal chemotherapy. The area under the ROC curve was 0.88.For immunocompetent patients with pulmonary Scedosporium spp infection, surgical therapy may not be associated with reduced mortality. Surgical excision could be considered but is not imperative in this group of patients.


Subject(s)
Lung Diseases, Fungal/drug therapy , Lung Diseases, Fungal/surgery , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/surgery , Scedosporium/drug effects , Adult , Aged , Aged, 80 and over , Antifungal Agents/therapeutic use , Drug Resistance, Fungal/physiology , Female , Humans , Immunocompromised Host/drug effects , Lung Diseases, Fungal/microbiology , Lung Diseases, Fungal/mortality , Male , Middle Aged , Mortality/trends , Mycoses/drug therapy , Mycoses/epidemiology , Mycoses/microbiology , Mycoses/mortality , Observational Studies as Topic , Postoperative Care , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/mortality , Retrospective Studies , Scedosporium/isolation & purification , Voriconazole/administration & dosage , Voriconazole/therapeutic use
17.
J Am Podiatr Med Assoc ; 109(5): 374-378, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31599670

ABSTRACT

Onychomycosis is a chronic fungal infection of the nail that is recalcitrant to treatment. It is unclear why normally effective antifungal therapy results in low cure rates. Evidence suggests that there may be a plethora of reasons that include the limited immune presence in the nail, reduced circulation, presence of commensal microbes, and fungal influence on immune signaling. Therefore, treatment should be designed to address these possibilities and work synergistically with both the innate and adaptive immune responses.


Subject(s)
Ascomycota/pathogenicity , Nails/immunology , Onychomycosis/drug therapy , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Ascomycota/drug effects , Drug Resistance, Fungal/physiology , Humans , Nails/metabolism , Nails/microbiology , Onychomycosis/immunology , Onychomycosis/metabolism
18.
Res Microbiol ; 170(8): 417-425, 2019.
Article in English | MEDLINE | ID: mdl-31562919

ABSTRACT

ABC transporters of the Pleiotropic Drug Resistance (PDR) family are the main actors of antifungal resistance in pathogenic fungi. While their involvement in clinical resistant strains has been proven, their transport mechanism remains unclear. Notably, one hallmark of PDR transporters is their asymmetry, with one canonical nucleotide-binding site capable of ATP hydrolysis while the other site is not. Recent publications reviewed here show that the so-called "deviant" site is of crucial importance for drug transport and is a step towards alleviating the mystery around the existence of non-catalytic binding sites.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Antifungal Agents/metabolism , Candida albicans/metabolism , Drug Resistance, Fungal/physiology , Antifungal Agents/pharmacology , Binding Sites/physiology , Biological Transport/physiology , Candida albicans/drug effects , Candidiasis/drug therapy , Candidiasis/pathology , Humans
19.
Fungal Genet Biol ; 131: 103247, 2019 10.
Article in English | MEDLINE | ID: mdl-31247322

ABSTRACT

Invasive aspergillosis caused by intrinsically resistant non-fumigatus Aspergillus species displays a poor outcome in immunocompromised patients. The polyene antifungal amphotericin B (AmB) remains to be "gold standard" in the treatment of invasive fungal infections. Aspergillus terreus is innately resistant to AmB, in vivo and in vitro. Till now, the exact mode of action in polyene resistance is not well understood. This review highlights the underlying molecular basis of AmB resistance in A. terreus, displaying data obtained from AmB susceptible A. terreus and AmB resistant A. terreus strains. The effect of AmB on main cellular and molecular functions such as fungal respiration and stress response pathways will be discussed in detail and resistance mechanisms will be highlighted. The fungal stress response machinery seems to be a major player in the onset of AmB resistance in A. terreus.


Subject(s)
Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillus/drug effects , Drug Resistance, Fungal/physiology , Polyenes/therapeutic use , Amphotericin B/metabolism , Animals , Antifungal Agents/metabolism , Aspergillosis/metabolism , Aspergillosis/microbiology , Aspergillus/metabolism , Cell Wall/drug effects , Cell Wall/metabolism , Ergosterol/metabolism , Heat-Shock Proteins/metabolism , Humans , Lipid Bilayers/metabolism , Mice , Mitochondria/drug effects , Mitochondria/metabolism , Oxidative Stress/drug effects , Polyenes/metabolism
20.
Sci Total Environ ; 681: 516-523, 2019 Sep 01.
Article in English | MEDLINE | ID: mdl-31121401

ABSTRACT

Agrochemicals such as the non-azoles, used to improve crop productivity, poses severe undesirable effects on the environment and human health. In addition, they induce cross-resistance (CR) with clinical drugs in pathogenic fungi. However, till date emphasis has been given to the role of azoles on the induction of CR. Herein, we analyzed the effect of a non-azole agrochemical, pyraclostrobin (PCT), on the antifungal susceptibility and virulence of the human and animal pathogens Cryptococcus gattii and C. neoformans. We determined the minimum inhibitory concentration (MIC) of fluconazole (FLC), itraconazole, ravuconazole, amphotericin B, and PCT on colonies: (i) that were not exposed to PCT (non-adapted-NA-cultures), (ii) were exposed at the maximum concentration of PCT (adapted-A-cultures) and (iii) the adapted colonies after cultivation 10 times in PCT-free media (10 passages-10p-cultures). Our results showed that exposure to PCT induced both temporary and permanent CR to clinical azoles in a temperature-dependent manner. With the objective to understand the mechanism of induction of CR through non-azoles, the transcriptomes of NA and 10p cells from C. gattii R265 were analyzed. The transcriptomic analysis showed that expression of the efflux-pump genes (AFR1 and MDR1) and PCT target was higher in resistant 10p cells than that in NA. Moreover, the virulence of 10p cells was reduced as compared to NA cells in mice, as observed by the differential gene expression analysis of genes related to ion-metabolism. Additionally, we observed that FLC could not increase the survival rate of mice infected with 10p cells, confirming the occurrence of permanent CR in vivo. The findings of the present study demonstrate that the non-azole agrochemical PCT can induce permanent CR to clinical antifungals through increased expression of efflux pump genes in resistant cells and that such phenomenon also manifests in vivo.


Subject(s)
Agrochemicals , Antifungal Agents , Cryptococcus gattii/physiology , Drug Resistance, Fungal/physiology , Strobilurins/toxicity , Animals , Cryptococcus neoformans , Humans , Mice , Microbial Sensitivity Tests
SELECTION OF CITATIONS
SEARCH DETAIL